The mitochondria play a crucial multifunctional role in the progression of malignant tumors. Therefore, researchers are working to understand the link between mitochondrial DNA mutations and abnormalities in mitochondrial-associated proteins and cancer development and progression.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Monte Rosa Therapeutics Inc. has divulged molecular glues as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer and amyloidosis.
Cell division cycle 20 homolog (CDC20) is a key regulatory protein involved in mitotic progression. Aberrant overexpression of CDC20 has been implicated in tumorigenesis and is associated with poor prognosis in several cancers, including triple-negative breast cancer.
To overcome the current limitations of antitumor immunotherapy, in situ vaccine platforms based on intelligent microbes are gaining increased attention due to their ability to sustainably deliver drugs locally without causing severe systemic risks.
Phosphoinositide signaling pathways have been implicated in the metabolic alterations associated with various human diseases, including breast cancer. The phosphatidylinositol-5-phosphate 4-kinase (PIP4K) family catalyzes the phosphorylation of phosphatidylinositol-5-phosphate (PI5P) to produce phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), a lipid that regulates signaling pathways associated with cancer cell growth and metastasis.
Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ESR1 degradation inducers reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
